{"name":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","slug":"genrix-shanghai-biopharmaceutical-co-ltd","ticker":"","exchange":"","domain":"genrixshanghaibiopharmaceutical.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"GR1803","genericName":"GR1803","slug":"gr1803","indication":"Advanced solid tumors (Phase 3 development)","status":"phase_3"},{"name":"Anti-CD38 Monoclonal Antibody","genericName":"Anti-CD38 Monoclonal Antibody","slug":"anti-cd38-monoclonal-antibody","indication":"Multiple myeloma","status":"phase_1"},{"name":"GR1501 high dose","genericName":"GR1501 high dose","slug":"gr1501-high-dose","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"GR1802 injection","genericName":"GR1802 injection","slug":"gr1802-injection","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"GR1801","genericName":"GR1801","slug":"gr1801","indication":"Other","status":"phase_3"},{"name":"GR2001","genericName":"GR2001","slug":"gr2001","indication":"Other","status":"phase_3"},{"name":"GR1501 low dose","genericName":"GR1501 low dose","slug":"gr1501-low-dose","indication":"Other","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"IL-17A antibody","genericName":"IL-17A antibody","slug":"il-17a-antibody","indication":"Psoriasis","status":"phase_2"}]}],"pipeline":[{"name":"GR1801","genericName":"GR1801","slug":"gr1801","phase":"phase_3","mechanism":"GR1801 is an investigational therapeutic in phase 3 development by Genrix Biopharmaceutical, but its specific mechanism of action is not publicly disclosed.","indications":[],"catalyst":""},{"name":"GR1803","genericName":"GR1803","slug":"gr1803","phase":"phase_3","mechanism":"GR1803 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T cell responses.","indications":["Advanced solid tumors (Phase 3 development)"],"catalyst":""},{"name":"GR2001","genericName":"GR2001","slug":"gr2001","phase":"phase_3","mechanism":"GR2001 is an investigational biopharmaceutical in phase 3 development by Genrix, but its specific mechanism of action is not publicly disclosed.","indications":[],"catalyst":""},{"name":"Anti-CD38 Monoclonal Antibody","genericName":"Anti-CD38 Monoclonal Antibody","slug":"anti-cd38-monoclonal-antibody","phase":"phase_1","mechanism":"Monoclonal antibody targeting CD38","indications":["Multiple myeloma"],"catalyst":""},{"name":"GR1501 high dose","genericName":"GR1501 high dose","slug":"gr1501-high-dose","phase":"phase_3","mechanism":"GR1501 high dose is a small molecule that targets the PD-1 receptor.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"GR1501 low dose","genericName":"GR1501 low dose","slug":"gr1501-low-dose","phase":"phase_3","mechanism":"GR1501 is a low-dose drug that targets a specific molecular pathway.","indications":[],"catalyst":""},{"name":"GR1802 injection","genericName":"GR1802 injection","slug":"gr1802-injection","phase":"phase_3","mechanism":"GR1802 injection is a monoclonal antibody targeting the PD-1 receptor.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"IL-17A antibody","genericName":"IL-17A antibody","slug":"il-17a-antibody","phase":"phase_2","mechanism":"IL-17A antibody targets the IL-17A receptor","indications":["Psoriasis","Plaque psoriasis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQdDJqZko5NS1lZWlQMndhQWpkQ2tYekpoNHRXV3k4dDdLUHB4Yy12TkNwMzhQaDdSLTRLdWJpbEhXbm5tMTE5SWstVGppSkI1aWlTMEJOV1pNWVA4d0dtaE0wSHJKd1lnSmo0WXhHSTlzMUc4ZjcwTVVYOVBXckRyMGZiQW1lMHl2SDVvbFRkbVIzQXpXeng3UnZoZC1ZNnNP?oc=5","date":"2026-03-04","type":"deal","source":"BioWorld News","summary":"UCB inks $1.1B deal for Antengene’s autoimmune bispecific TCE - BioWorld News","headline":"UCB inks $1.1B deal for Antengene’s autoimmune bispecific TCE","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxQdEFnQktFM210eXdiZmRhVlE4Y3FUTndfak5Cell5OFgyR1Z1QWxsaks4TzU0NTBvZlJIc0o3enpwWTlTYXBFR3o4eFZNZUg2QUpEZGN5Z3ZsTFRqTmZOMVBSZVpoa1YxT3ZHbFlaVVJOZHBWZjFkSE1jSFpXSVVpYVl2U1VhSHRJS1daVHZkSHAtLW5nbW1aeWZIZk9CQUxLNnVlYVF6VVZNRVdtT3ZpVzhMVkI1ODFPLUpqLWpBU3dEVnpWSldBX1JaTmZaX1VTUFJEc0hubWtXZGVwWmw4UmlyLUpTbk5MYVhCRENwaVByRVhzZXhobF9wUGJNYzUtMGNzWEFqbkN3enFKdFplVjJnYzVPQVduMDAzZ1Jn?oc=5","date":"2025-12-08","type":"regulatory","source":"globenewswire.com","summary":"Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma - globenewswire.com","headline":"Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxOTFRWdk1faWotclNmbkphcC1XeHJ0R0s0UnkyYnF6LVBrQjEycDZJSERQZnk4ZktwUTBHbG1wVTFSU1FxOHVTWUx3WTFnd2I3VlpnWDVEbUVEU05NN29zWlA3ZkFkMWU3YmotRno2S29NdUhWRTJadnc3SzFacVhnTjRwODJENnZXYVh4QzYxSjIwMG4zMnNjaG94VXdRellLZW5PbkpwTnY5RGl3VTlpUW5jYmtDb09iTTg5RHQ0ZG9tTDl0Zk1GQV9nS1R5WUxsOXpkeWtRcURYVEJvQ0dmNnZZSXlYUnBobk1PYw?oc=5","date":"2025-10-06","type":"pipeline","source":"PR Newswire","summary":"Lupus Nephritis Market to Advance at a CAGR of 8.5% During the Forecast Period (2025-2034) | DelveInsight - PR Newswire","headline":"Lupus Nephritis Market to Advance at a CAGR of 8.5% During the Forecast Period (2025-2034) | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPU3ZOdTlaZDMxZ09IMkFUazlzVEtuS1A0RHg3b3dqTkQ0bjYtWFdjbC1KdjZPRWhZUXJORmhwUnI0dThfLVZJVC1QSnktSUg4Mm5ZOVBPbVJOWnRTSmZFWXN1SldQV3VYYU82dEp5RXE2NU96SEpMVHVNYVh5aUMtbnZhVHQ4cTBYQ2xjX1lHZjZBcDdV?oc=5","date":"2025-08-14","type":"trial","source":"Yahoo Finance","summary":"Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Yahoo Finance","headline":"Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveIn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOSXpxeWZydHlDUTZXekpJQ29teFdNQjFhV1ZSakZFWm1UNU1wN3lYN0ExVTlXOXcybDNRN1IwU0FGVkwzT0tZNXJmNnl3UlhseUE4NTVLbUl0TVlFT0JYOEJLdzhtTVNSNkF0N1YyMnFMb0xXRFVMbjhoMVhsTUdDV1JUMGlac2lERGlKWFIydjM4Z1U0NTFmalU0SWtkcDAzOUdZRElnQQ?oc=5","date":"2025-06-12","type":"deal","source":"BioWorld News","summary":"Cullinan deals $712M to test Genrix bispecific TCE in autoimmune - BioWorld News","headline":"Cullinan deals $712M to test Genrix bispecific TCE in autoimmune","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOOWFqUnA2eWoydEp1eXVIZERSMXBCZi1MYkUzNDU5Vl9RUWNSRUNGaGFCb0tCQmNVWkkzLVBQTFJlQndwR0xGdV80VmZHUjNGb0VxV29VMTdYMzZpbjQ1ZVdraUN2QlR0ay0zdnFuUmdheUczUW5YMDA2ZVJxTWlmdEtmLWNCVXFQelpLTGxPWW5aYWQ2a0E5dkRCU1pMeGVJMlZlUU5DY25ScVRjV1lGV3NpeWo?oc=5","date":"2025-06-05","type":"deal","source":"Contract Pharma","summary":"Cullinan Therapeutics Licenses Rights to Velinotamig from Genrix Bio - Contract Pharma","headline":"Cullinan Therapeutics Licenses Rights to Velinotamig from Genrix Bio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wJBVV95cUxOMjc1ZUUxTTNLRElmYnctUnpKbGNLZ1RwTWpkWnFzS0NWRUhodUpCQV9LRWFUMHJ5T1o0WVQzeHdWVWF2NzREZDRPbWxQUkFDUFIxQ043bmZrWFlRaG1kQWU1Qjc4eEMweXEtUnVBOFNJZHZPN21LdGxoWXIxZlhxbk1rR0drN2o1NWhnM3BfbG1EOGJNdzhYQkxfRG1henZRVVllcVVOLVppSmxid2ZwMnB0VzdfLWRmNFU5Y2s4MG1HRlZ5eDM5MVBVSEp6ZmJtRnpIbUIwTjRxcWlUUTNjaGhtVDBFUFFXaElBYTUyRFlNZ05lTHVqUmhua2ZrREQ2Tlg2UFh6MnQ4Ty0zOC03azVrb3JoV3ZJVG4tblA2RndFeFNzWDNESmxKbHU2U0ZtbjVtVDdZMnFVMEF2TVlCNm0yOUtIUnZfTzg5NDhuaGNwLVR2QlpZ?oc=5","date":"2025-06-04","type":"deal","source":"globenewswire.com","summary":"Cullinan Therapeutics Licenses Rights to Velinotamig, a - globenewswire.com","headline":"Cullinan Therapeutics Licenses Rights to Velinotamig, a","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxQYXlpWWtJNGNLZHJEeWRMRnR6R0E2SVY5eElibzV2ZDlyaGZ0cDNLd3Z4V2hIVWpoZlA1LUw5SEd6SHRHbWNva1VQcUExU1FQN1lWV3pBN2M4aUktay16cGpCc2pPc2xsOWlwUzBvMXFGbmduaG5OdE1mZEM5aEdlN3BsNU1LNER4eWtScEpHb1hKUllUWm1OSndEM3MySmF6d3VPY0Q5ZVFjclBWUG5TMGNpODhhYWdiUlFQbV94T0g1T3RyZ2FnOWlhS0Z1c0xpNnExUGJBMTJfSGNGR01paGlveU5mazNqMV9JM1FIX1FlSzUwSjJ4VEtBWjVtWTVfTmpteW9n?oc=5","date":"2024-11-19","type":"regulatory","source":"PR Newswire","summary":"Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight - PR Newswire","headline":"Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsigh","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxQUlBEN2JQMkVlejVsUDE0d0pQcXhDTHBHdE1nMmhzTVNERFBfTDkzWW83Yi1ZZEpBbHowUjA1S0VpNnJ2NXZnUHRJY09NUDVxZnp2WFNxc1I2Q0x3dTFldXhFNm5JUDR5MlA4a0tDeTUxYm5WYTZMVzZUczJHYjBHbDFFaDRiTDZTSlJNRzFnbHBjNUYwNkR3ejJGa3AweDlpeVdhdk5ucGJmSHctSTdHS3g5N2lMYU1fMDB3TlYtUlBScG4zYUI4bk5LQjVlaGt3blZ5OWRfdkVCY2NFcWYtZ1UxVGxrZWJtZExQSGxFYUN4c1ZSQWhaZkxhT1M1RXRudlNuRXNlMXQ3MzFPMkZTeFRvS3VVaHprWlpsazd1akZOUQ?oc=5","date":"2024-11-06","type":"trial","source":"PR Newswire","summary":"Severe Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire","headline":"Severe Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics ","sentiment":"neutral"}],"patents":[],"drugCount":8,"phaseCounts":{"phase_3":6,"phase_1":1,"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}